Document is current
Any future updates will be listed below
-
Authors
Castro, Cristina M. https://orcid.org/0000-0003-2609-1177
Corciulo, Carmen
Friedman, Benjamin https://orcid.org/0000-0001-8503-4653
Li, Zhi
Jacob, Samson
Fenyo, David https://orcid.org/0000-0001-5049-3825
Cronstein, Bruce N. https://orcid.org/0000-0002-4295-7383
-
Funding
Funding for this research was provided by:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (RO1-AR054897, RO1-AR056672)
NYU-HHC Clinical and Translational Science Institute (UL1-TR000038)
National Institutes of Health (T32GM136573)
National Institutes of Health (3RO1AR056672-07S1)
- License Information
-
More Information
Article History
Received: 10 February 2021
Accepted: 8 April 2021
First Online: 11 May 2021
Declarations
:
: Drs. Corciulo and Cronstein have received a patent for the use of intra-articular injection of liposomal preparations of adenosine and A2AR agonists for the treatment of osteoarthritis. In addition, Drs. Corciulo and Cronstein are among the founders of Regenosine, a company incorporated to develop adenosine receptor–related therapies for osteoarthritis.
: The New York University School of Medicine Institutional Animal Care and Use Committee approved all protocols for experimental procedures involving the use of animals according to US law.
: No human subjects were recruited in this study. This section therefore does not apply to this work.
: All authors stated above have reviewed and consented to the content of this publication.
